Determination of a mutational status of the BRAF gene in patients with metastatic colorectal cancer in routine
DOI: 10.32364/2587-6821-2026-10-7-3
I.D. Trotsenko, I.I. Andreyashkina, I.E. Khatkov
A.S. Loginov Moscow Clinical Scientific Center, Moscow, Russian Federation
Background: colorectal cancer (CRC) is one of the most common cancers in developed countries. The BRAF V600E mutation found in 8-10% of cases of metastatic CRC (mCRC) is a diagnostic, predictive and prognostic marker of the disease course. V600E (i. e., valine replacement with glutamic acid) is the most common CRC-associated subtype of BRAF mutation. Availability, scope, and time limits of a molecular genetic testing may be entity-specific.
Aim: to evaluate availability, scope and time limits of a molecular genetic testing in mCRC patients in routine clinical practice in Russia.
Materials and Methods: from January to April 2025, an anonymous online survey was conducted in oncologists, chemotherapists, and department heads who refer patients with mCRC for a molecular genetic testing. The survey including 12 questions was conducted on the website of the Moscow Cancer Society.
Results: 124 doctors from different Russian entities participated in the survey. On average, about 80% of mCRC patients are referred to a molecular genetic testing for the BRAF gene mutation. Approximately 20% of the responders are unaware of three classes of BRAF mutation. PCR is the main method of a molecular genetic testing for BRAF mutation. 31.5% of the doctors prefer avoiding a high throughput sequencing (NTS) to detect mCRC-associated mutations, 25.8% of practitioners prescribe an NTS test only if a hereditary abnormality is suspected. 43.5% of doctors wait for the test results for more than 15 days.
Conclusion: in our country, a BRAF mutation test is readily available due to various funding channels, while a lack of funding under the compulsory medical insurance program is one of the reasons to refuse from a BRAF mutation test. This indicates a need for measures to improve arrangement of the molecular genetic testing. Educational activities should also be carried out to increase oncologists' awareness of prognostic and predictive significance of the BRAF mutation associated with mCRC, as well as significance of the three classes and different subtypes of the BRAF mutation. Whenever possible, an effort should be made to refer mCRC patients for the molecular genetic testing before a start of a first-line therapy.
Keywords: colorectal cancer, BRAF mutation, molecular genetic testing, online survey.
For citation: Trotsenko I.D., Andreyashkina I.I., Khatkov I.E. Determination of a mutational status of the BRAF gene in patients with metastatic colorectal cancer in routine clinical practice: results of a survey of doctors in the Russian entities. Russian Medical Inquiry. 2025;10(7):480–488 (in Russ.). DOI: 10.32364/2587-6821-2026-10-7-3
ABOUT THE AUTHORS:
Ivan D. Trotsenko — C. Sc. (Med.), Executive Director of the Moscow Oncological Society, Senior Scientific Officer at the Department of General Oncology, A.S. Loginov Moscow Clinical Scientific Center; 86 build. 6, Entuziastov Road, Moscow, 111123, Russian Federation; ORCID iD 0000-0002-6667-0125
Irina I. Andreyashkina — Dr. Sc. (Med.), Deputy Chief Freelance Oncologist at the Moscow Healthcare Department, Leading Scientific Officer, A.S. Loginov Moscow Clinical Scientific Center; 86 build. 6, Entuziastov Road, Moscow, 111123, Russian Federation; ORCID iD 0000-0003-2646-499X
Igor E. Khatkov — Dr. Sc. (Med.), Professor, Academician of the Russian Academy of Sciences, Chief Freelance Oncologist at the Moscow Healthcare Department, Director of A.S. Loginov Moscow Clinical Scientific Center; 86 build. 6, Entuziastov Road, Moscow, 111123, Russian Federation; ORCID iD 0000-0002-4088-8118
Contact information: Ivan D. Trotsenko, e-mail: ivan.trotsenko@mosoncolog.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 17.10.2025.
Revised 13.11.2025.
Accepted 25.11.2025.
2. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. DOI: 10.3322/caac.21660<br>
3. Злокачественные новообразования в России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2024.Malignant neoplasms in Russia in 2023. Kaprin A.D., Starinsky V.V., Shakhzadova A.O., eds. Moscow: P.A. Herzen Moscow Oncology Research Institute — branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation; 2024 (in Russ.).<br>
4. Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2024.The state of oncological care for the population of Russia in 2023. Kaprin A.D., Starinsky V.V., Shakhzadova A.O., eds. Moscow: P.A. Herzen Moscow Oncology Research Institute — branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation; 2024 (in Russ.).<br>
5. Телетаева Г.М., Дегтярева Е.А., Семенова А.И. и др. Молекулярно-генетический профиль колоректального рака: клиническое значение типичных и агностических мута-ций. Вопросы онкологии. 2024;70(5):854–863. DOI: 10.37469/0507-3758-2024-70-5-854-863Teletaeva G.M., Degtiareva E.A., Semenova A.I. Molecular landscape of colorectal cancer: clinical significance of common and agnostic mutations. Problems in Oncology. 2024;70(5):854–863 (in Russ.). DOI: 10.37469/05073758-2024-70-5-854-863<br>
6. Grassi E., Corbelli J., Papiani G. et al. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Front Oncol. 2021;11:601722. DOI: 10.3389/fonc.2021.601722<br>
7. Федянин М.Ю., Эльснукаева Х.Х.-М., Демидова И.А. и др. Колоректальный рак с мутацией в гене BRAF в Российской Федерации: эпидемиология и клинические осо-бенности. Результаты многоцентрового исследования. Медицинский совет. 2021;(4S):52–63. DOI: 10.21518/2079-701X-2021-4S-52-63Fedyanin M.Yu., Ehlsnukaeva Kh.Kh.-M., Demidova I.A. et al. Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia. Medical Council. 2021;(4S):52–63 (in Russ.). DOI: 10.21518/2079-701X-2021-4S-52-63<br>
8. Riely G.J., Ahn M.J., Clarke J.M. et al. Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report. J Thorac Oncol. 2025;20(10):1538–1547. DOI: 10.1016/j.jtho.2025.05.023<br>
9. Schadendorf D., Dummer R., Flaherty K.T. et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. Eur J Cancer. 2024;204:114073. DOI: 10.1016/j.ejca.2024.114073<br>
10. Cervantes A., Adam R., Roselló S. et al.; ESMO Guidelines Committee. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32. DOI: 10.1016/j.annonc.2022.10.003<br>
11. Morris V.K., Kennedy E.B., Baxter N.N. et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678–700. DOI: 10.1200/JCO.22.01690<br>
12. Tabernero J., Grothey A., Van Cutsem E. et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39:273–284. DOI: 10.1200/JCO.20.02088<br>
13. Mao M., Tian F., Mariadason J.M. et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19:657–667. DOI: 10.1158/1078-0432.CCR-11-1446<br>
14. Corcoran R.B., Atreya C.E., Falchook G.S. et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015;33:4023–4031. DOI: 10.1200/JCO.2015.63.2471
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать